ALLO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Allogene Therapeutics Inc (ALLO) is not a strong buy for a beginner, long-term investor at this time. While there are positive analyst ratings and potential catalysts in the pipeline, the company's financial performance is weak, and there are no significant trading signals or recent news to suggest immediate upside. Given the neutral technical indicators and lack of strong institutional or insider activity, it is better to hold off on investing in this stock until more favorable conditions arise.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 55.409, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 2.36 with resistance at 2.618 and support at 2.102, suggesting limited immediate upside.
Analysts have raised price targets and remain optimistic about the upcoming ALPHA3 study results in April. The potential for $1B in risk-adjusted sales for cema-cel by 2033 is a long-term positive catalyst.
The company's financials show significant declines in net income (-35.25% YoY) and EPS (-39.29% YoY). Gross margin has dropped to 0, indicating no profitability. There is no recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q4 2025, revenue remained at 0 with no growth. Net income dropped to -$38.81M (-35.25% YoY), and EPS declined to -0.17 (-39.29% YoY). Gross margin fell to 0, reflecting poor financial health.
Analysts are optimistic with price targets raised to $5-$8 and ratings upgraded to Buy/Outperform. They are confident in the ALPHA3 study's success and long-term potential for cema-cel. However, the stock remains speculative with no immediate catalysts for a price surge.
